Relation Between Levels of Plasma Pentraxin 3 (PTX3) And Diabetic retinopathy in Patients with Type 2 diabetes mellitus

Abstract

iabetic retinopathy (DR) is a chronic progressive, potentially sight-threatening disease of the retinal microvasculature associated with the prolonged hyperglycemia and other conditions linked to diabetes mellitus such as hypertension. Legal blindness due to DR is estimated to be 25 times more common among the diabetic population than in those without diabetes. Pentraxin 3 (PTX3) is an acute-phase reactant characterized by a cyclic multimeric structure. Pentraxin 3, in the form of a long pentraxin, is produced by peripheral tissues and reflects impaired vascular endothelial function. The aim of the present study was to assess the relationship between serum Pentraxin 3 (PTX3) in type 2 Diabetes and retinopathy. This study was conducted on 70 patients with type 2 DM and 20 healthy subjects as a control with their ages ranging from 40-70. They were collected from outpatient diabetes and endocrinology clinic at El Demerdash Hospital, Ain-Shams University and outpatient diabetes and endocrinology clinic at National Institute of Diabetes and Endocrinology; it was conducted from January to July, 2019. The study was explained